



Corrigendum to “The changing landscape of Heart Failure: translating management into the modern era” [European Journal of Internal Medicine (2026) 106633]

Cristina Madaudo^{a,b}, Wasyla Ibrahim^a, Daniela Noakes^{a,c}, Daniel Bromage^{a,c}, Gianfranco Sinagra^d, Theresa McDonagh^{a,c}, Antonio Cannata^{a,c,*}

^a British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK

^b Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Cardiology Unit, University of Palermo, University Hospital P. Giaccone, 90127, Palermo, Italy

^c Cardiology Department, King's College Hospital NHS Foundation Trust, London, UK

^d Azienda Sanitaria Universitaria Giuliano-Isontina, Università di Trieste, Trieste, Italy

The authors regret that in [Figure 1](#) the name of the drug Sacubitril/Valsartan was incorrectly reported as sacubitril valsartan. This was a typographical error, and the figure has now been corrected as below.

This correction does not affect the scientific conclusions of the article. The authors would like to apologise for any inconvenience caused.




Fig. 1. Current management and future perspective of treatment for heart failure.

DOI of original article: <https://doi.org/10.1016/j.ejim.2025.106633>.

* Corresponding author. Antonio Cannata.

E-mail address: antonio.cannata@kcl.ac.uk (A. Cannata).

<https://doi.org/10.1016/j.ejim.2026.106703>

Available online 12 January 2026

0953-6205/© 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).